৳ 0.00
Your Complete HealthCare Solution - Right Here
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.
৳ 0.00
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.



Quantity:
Products
Payment
Delivery
Therapy with lipid‑altering agents should be part of multi‑risk factor intervention in patients at high risk of atherosclerotic vascular disease due to hypercholesterolemia.
Adjunct to diet when non‑pharmacologic measures are inadequate.
Primary Hyperlipidemia: Reduction of total‑C, LDL‑C, Apo B, TG, non‑HDL‑C; increase HDL‑C in heterozygous familial/non‑familial hyperlipidemia or mixed hyperlipidemia.
HoFH: Reduction of total‑C and LDL‑C, adjunct to LDL apheresis or if unavailable.
Atorvastatin: Inhibits HMG‑CoA reductase, reduces cholesterol synthesis, increases hepatic LDL receptors, lowers LDL production.
Ezetimibe: Inhibits intestinal cholesterol absorption via NPC1L1 transporter, reduces hepatic cholesterol stores, increases clearance from blood. Complementary to statins.
Range: 10/10 mg to 80/20 mg daily.
Starting dose: 10/10 mg or 20/10 mg daily.
For >55% LDL‑C reduction: 40/10 mg daily.
HoFH: 40/10 mg or 80/10 mg daily.
Contraindicated in active liver disease.
Renal impairment: monitor for myopathy; no dose adjustment needed.
Increased risk of myopathy with fibrates, niacin, cyclosporine, CYP3A4 inhibitors, gemfibrozil, digoxin, oral contraceptives, colchicine, warfarin.
Active liver disease
Persistent elevated transaminases
Hypersensitivity to components
Rhabdomyolysis, myopathy, liver enzyme abnormalities, myalgia, abdominal pain, increased hepatic enzymes.
Category X: Contraindicated in pregnancy.
Cholesterol needed for fetal development.
Discontinue during pregnancy.
Unknown if atorvastatin passes into milk; similar drugs do.
Cases of myopathy/rhabdomyolysis reported with atorvastatin + colchicine.
Temporarily discontinue in acute serious conditions suggestive of myopathy.
Liver enzymes: Test before therapy and as clinically indicated. Discontinue if serious liver injury occurs.
Drug Class: Lipid-lowering combination therapy
Components:
Atorvastatin: A statin that reduces cholesterol production in the liver.
Ezetimibe: A cholesterol absorption inhibitor that reduces cholesterol uptake from the intestine.
Purpose:
Used to lower LDL cholesterol (“bad cholesterol”) more effectively than either drug alone.
Helps reduce triglycerides and increase HDL cholesterol (“good cholesterol”).
Reduces risk of cardiovascular events (heart attack, stroke, angina).
Dosage Forms: Tablets combining both agents (commonly 10/10 mg, 10/20 mg, 10/40 mg, 10/80 mg).
Common Brand Names: Atozet, Liptruzet, others depending on region.
.
Enhanced LDL Reduction: More effective at lowering “bad cholesterol” (LDL) than atorvastatin or ezetimibe alone.
Dual Mechanism:
Atorvastatin reduces cholesterol production in the liver.
Ezetimibe reduces cholesterol absorption from the intestine.
Improves Lipid Profile: Helps lower triglycerides and raise HDL (“good cholesterol”).
Cardiovascular Protection: Reduces risk of heart attack, stroke, and other cardiovascular events.
Useful in Resistant Cases: Beneficial for patients who do not achieve target cholesterol levels with statins alone.
Convenience: Fixed-dose combination tablet improves compliance compared to taking two separate medicines.





